Osteopore (ASX: OSX) continues penetrating global markets with breakthrough bone regeneration products (w/ Carl Runde)

Osteopore (ASX: OSX) chief financial officer Carl Runde joins Small Caps to discuss the company’s breakthrough bioresorbable products which facilitate bone regeneration. The current target markets for Osteopore’s products are worth more than US$103 billion. Compared to current procedures, Osteopore’s bone regeneration products offer improved patient outcomes while also reducing overall healthcare costs.See omnystudio.com/listener for privacy information.